Insider Buying: Athenex Inc (ATNX) EVP Purchases 1,000 Shares of Stock
Athenex Inc (NASDAQ:ATNX) EVP Rudolf Kwan acquired 1,000 shares of the stock in a transaction on Monday, November 19th. The stock was acquired at an average cost of $11.70 per share, for a total transaction of $11,700.00. The acquisition was disclosed in a filing with the SEC, which is available through this link.
Rudolf Kwan also recently made the following trade(s):
- On Wednesday, November 14th, Rudolf Kwan acquired 10,000 shares of Athenex stock. The stock was acquired at an average cost of $10.49 per share, for a total transaction of $104,900.00.
Shares of NASDAQ:ATNX traded down $0.20 during trading on Monday, hitting $11.78. 369,400 shares of the stock were exchanged, compared to its average volume of 325,359. The firm has a market capitalization of $801.39 million, a price-to-earnings ratio of -5.08 and a beta of 0.31. The company has a debt-to-equity ratio of 0.30, a current ratio of 4.46 and a quick ratio of 3.86. Athenex Inc has a 12-month low of $9.83 and a 12-month high of $20.90.
Several large investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC boosted its stake in shares of Athenex by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 31,296 shares of the company’s stock worth $486,000 after acquiring an additional 11,125 shares in the last quarter. Man Group plc purchased a new stake in shares of Athenex during the 3rd quarter worth approximately $201,000. Perceptive Advisors LLC boosted its stake in shares of Athenex by 1,410.3% during the 3rd quarter. Perceptive Advisors LLC now owns 2,869,528 shares of the company’s stock worth $44,592,000 after acquiring an additional 2,679,528 shares in the last quarter. Tekla Capital Management LLC purchased a new stake in shares of Athenex during the 3rd quarter worth approximately $708,000. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of Athenex during the 3rd quarter worth approximately $146,000. 20.93% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on ATNX shares. BidaskClub lowered Athenex from a “sell” rating to a “strong sell” rating in a report on Saturday, October 6th. JPMorgan Chase & Co. raised Athenex from a “neutral” rating to an “overweight” rating and lowered their price objective for the company from $24.00 to $15.00 in a report on Thursday. LADENBURG THALM/SH SH began coverage on Athenex in a research note on Thursday, October 25th. They set a “buy” rating and a $27.00 price target on the stock. Zacks Investment Research lowered Athenex from a “hold” rating to a “sell” rating in a research note on Friday, August 17th. Finally, ValuEngine lowered Athenex from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Athenex has an average rating of “Hold” and a consensus price target of $22.00.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.